Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | Fecal microbiota transplantation for the treatment of aGvHD of the gut

Roni Shouval, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on evidence supporting the use of fecal microbiota transplantation (FMT) for the treatment of acute graft-versus-host disease (aGvHD) of the gut. In recent years, studies have shown an association between the gut microbiota and the severity of GvHD, and microbiota modulation with FMT has emerged as a promising strategy to prevent and treat GvHD. Increasingly larger studies in patients with steroid-refractory (SR) and steroid-dependent (SD) aGvHD are showing the benefit of FMT. Nevertheless, there is a high variability in FMT preparation and administration techniques, as well as in response rates (RR) across different studies. It is thus important to perform further studies to clarify the role of FMT in the treatment of aGvHD of the gut. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.